Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) generates a steady flow of news related to its late-stage biopharmaceutical pipeline in ophthalmology and neuro-ophthalmology. Company announcements highlight clinical trial milestones, regulatory designations, capital markets activity, and scientific presentations that are relevant for investors and observers tracking developments in optic neuropathies and retinal disease.
Recent news releases describe the advancement of Privosegtor, a peptoid small-molecule neuroprotective candidate, into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy. Oculis has reported positive Phase 2 ACUITY data in acute optic neuritis and disclosed that Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Orphan Drug designation from the FDA and EMA. Updates often cover trial design, endpoints such as low-contrast visual acuity, and planned global enrollment.
News coverage also follows OCS-01 eye drops in Phase 3 DIAMOND studies for diabetic macular edema, including the use of the company’s OPTIREACH technology to deliver dexamethasone topically to the retina. In addition, Oculis issues releases on Licaminlimab for dry eye disease, participation in major medical meetings such as the J.P. Morgan Healthcare Conference and ophthalmology congresses, and insider transaction notifications related to restricted stock unit vesting and director share purchases.
For readers monitoring OCS, this news feed provides company-sourced updates on clinical progress, regulatory interactions, financing transactions disclosed in Form 6-K filings, and scientific data presentations. It can be a useful reference for following how Oculis advances its investigational therapies for optic neuritis, NAION, diabetic macular edema, and dry eye disease over time.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in four major investor conferences in May 2025:
- Bio€quity Europe in Bruges (May 12-14)
- Bank of America Healthcare Conference in Las Vegas (May 13-15)
- H.C. Wainwright BioConnect at Nasdaq in New York (May 20)
- Stifel Virtual Ophthalmology Forum (May 27)
CEO Riad Sherif and CFO Sylvia Cheung will present company updates and participate in fireside chats. One-on-one meetings will be available for interested investors through sponsoring institutions. Webcast links will be posted on the company's website.
Oculis Holding (Nasdaq: OCS) announces upcoming presentations of its late-stage pipeline at major ophthalmology conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress.
Key highlights include:
- OCS-01 eye drops for DME (Diabetic Macular Edema) - First non-invasive treatment showing positive Phase 3 DIAMOND program results
- Licaminlimab (OCS-02) for dry eye disease (DED) - Phase 2b RELIEF trial data featuring a genetic biomarker-based personalized approach
Presentations will feature insights from the DME AWARE Delphi Study on unmet needs in patient management and detailed efficacy data from the DIAMOND Stage 1 trial. Distinguished speakers include Dr. Anat Loewenstein, Dr. Carl Danzig, Dr. Anat Galor, and Dr. David Almeida, leading experts in ophthalmology.
Oculis Holding, a global biopharmaceutical company, announces upcoming presentations of its late-stage pipeline at major ophthalmology conferences including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress.
Key highlights include the DME AWARE Delphi Study interim results and insights from the Phase 3 DIAMOND program for OCS-01, potentially the first non-invasive treatment for DME. The company will also present data from the Phase 2b RELIEF trial of Licaminlimab (OCS-02) for dry eye disease (DED), featuring a genetic biomarker-based approach.
Notable presentations will be delivered by distinguished experts including Dr. Sharon Klier, Dr. Anat Loewenstein, Dr. Carl Danzig, Dr. Anat Galor, Dr. Riad Sherif, and Dr. David Almeida across multiple sessions focusing on retinal diseases and innovative treatments.
Oculis Holding AG (Nasdaq: OCS) has announced an update to its share capital structure. The company has issued 589,974 new registered ordinary shares with a nominal value of CHF 0.01 each. This issuance consists of:
- 310,941 shares issued for equity awards under the Company's Stock Option and Incentive Plan
- 279,033 shares issued through EBAC warrant exercises
Following these issuances, which occurred between January 1, 2024, and December 31, 2024, Oculis's total registered shares have increased to 54,533,674. The change has been officially registered with the Zug Commercial Register.
Oculis Holding AG (Nasdaq: OCS) and EURETINA have announced the 2025 Ramin Tadayoni Award, continuing their collaboration to honor the legacy of Professor Tadayoni, who passed away on April 19, 2024. The award, worth €30,000 for research support plus €5,000 for the candidate, aims to support exceptional postgraduate scholars in retina research.
Applications will be accepted until May 12, 2025, with the winner to be announced at the EURETINA Congress in Paris (September 4-7, 2025). Dr. Andrea Govetto was named the inaugural recipient in 2024 for his work on developing a computational model of fluid flow and retinal tissue deformation in macular edema.
Professor Tadayoni served as Oculis' Chief Scientific Officer and was a distinguished figure in ophthalmology, having authored over 320 medical articles and received numerous prestigious awards including the Jules Gonin Award.
Oculis (OCS) is hosting an R&D Event to showcase progress on its three pipeline assets. Key highlights include:
- Updates on DIAMOND and EMERALD Phase 3 trials for DME with >800 enrolled patients and topline data expected in Q2 2026
- Development plans for Licaminlimab (OCS-02) in dry eye disease with Phase 2/3 study starting in H2 2025
- New data from ACUITY Phase 2 trial for Privosegtor (OCS-05) in acute optic neuritis
The company also announced expansion of Privosegtor development into non-arteritic anterior ischemic optic neuropathy (NAION) and multiple sclerosis relapses. A follow-up investor meeting is scheduled in Iceland on April 29, 2025.
Oculis (Nasdaq: OCS) has completed enrollment for its Phase 3 DIAMOND trials evaluating OCS-01 eye drops in diabetic macular edema (DME). The program consists of two double-masked, randomized, multi-center trials with over 800 patients across 119 sites globally.
The DIAMOND (DIAbetic Macular edema patients ON a Drop) program represents the first-ever pivotal trial for a topical DME treatment. Topline data is expected in Q2 2026, followed by an NDA submission. If approved, OCS-01 would become the first topical eye drop treatment for DME, addressing unmet needs for early intervention and patients with inadequate anti-VEGF therapy response.
Oculis announced the vesting and settlement of previously granted Restricted Stock Units (RSUs) for company directors. The notification specifically pertains to transactions by Persons Discharging Managerial Responsibilities, with particular reference to director Riad Sherif's RSU vesting in April 2025.
Oculis Holding AG (Nasdaq: OCS) announces an upcoming R&D Day scheduled for April 15, 2025, from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. The event, available both in-person and virtually, will showcase updates on the company's late-stage clinical candidates and development strategy.
The presentation will feature prominent Key Opinion Leaders (KOLs) specializing in retina, inflammation, precision medicine, and neuro-ophthalmology from prestigious institutions including USC, University of Nevada, UC Irvine, University of Bern, University of Miami, Mount Sinai, McGill University, and Stanford University.
Key topics include:
- Updates on Phase 3 DIAMOND trials of OCS-01 eye drops for diabetic macular edema (DME)
- Licaminlimab (OCS-02) development plans for dry eye disease (DED)
- Expanded analysis of ACUITY Phase 2 trial
- Development plans for Privosegtor (OCS-05) in acute optic neuritis
Oculis has disclosed multiple notifications regarding transactions executed by a Person Discharging Managerial Responsibilities (PDMR) under a pre-planned 10b5-1 trading plan. The sales transactions were conducted by R. Sherif over five consecutive days from March 14-20, 2025, in compliance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934.